Opinion|Videos|May 15, 2024
Optimizing Complex Pulmonary Arterial Hypertension Care: Enhancing Adherence and Outcomes
Author(s)Ioana Preston, MD
Focusing on the complexity of PAH management, Ioana Preston, MD, discusses the importance of combination therapies, close monitoring, and provides insight on counseling patients through treatment.
Advertisement
Episodes in this series
Video content above is prompted by the following question:
- How does the complexity of pulmonary arterial hypertension (PAH) management, including the need for combination therapies and close monitoring, impact patient adherence and disease control?
Advertisement
Related to this article
ASPEN links green sputum to neutrophils and exacerbations; brensocatib (DPP1) lowers purulence, while meta-analysis supports fewer flare-ups in bronchiectasis.
Narcolepsy and idiopathic hypersomnia can go undiagnosed for years, and Epworth and RU-SATED screening help clinicians spot true sleepiness sooner.
At CHEST 2026, 3 speakers explained why respiratory medications stay expensive, assessed what recent federal, state, and industry fixes have achieved, and urged clinicians to use their voices on behalf of patients.
Experts at CHEST 2026 urge pulmonologists to keep lung cancer in mind for younger patients who never smoked, to order screening and biomarker testing themselves, and to advocate for patients' access to care.
FDA granted accelerated approval to dostarlimab-gxly for dMMR or MSI-H locally advanced rectal cancer based on interim phase 2 AZUR-1 results.
Phentolamine 0.75% (Ryzumvi) won FDA approval for presbyopia based on the phase 3 VEGA-2 and VEGA-3 trials.
Nearly 3 in 4 bariatric surgery candidates had clinical obesity, a phenotype that BMI alone did not distinguish from preclinical obesity.
Satralizumab, a first-in-class IL-6 receptor inhibitor, was approved for adults with thyroid eye disease based on the phase 3 SatraGO program.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Ryzumvi for Presbyopia, Expanding its Label
2
New CHEST Guidelines Offer a Road Map for Bronchiectasis
3
FDA Grants Accelerated Approval to Dostarlimab for dMMR Rectal Cancer
4
AAO 2026: Closing the Screening Gap in Diabetic Retinopathy
5